The GLP-1 pill is an alternative to injectable GLP-1 medication
United States Maintains Market Leadership with Commercial Insurance Coverage Demand for obesity GLP-1 treatment in the United States is expanding at a CAGR of 25.4%, driven by growing commercial insurance coverage and strong consumer awareness of available treatments
Tirzepatide with glycine follows the same stabilization rationale, and tirzepatide with B12 helps offset the energy dips that some patients experience during the first few weeks of treatment
Note: GLP-1 brands include Victoza, Trulicity, Saxenda, Ozempic, Rybelsus, Wegovy, and Mounjaro Source: IQVIA LAAD pharmacy claims, PlanTrak projected pharmacy claims
It carries strategic Aib substitutions to resist DPP-4 cleavage and a C20 fatty di-acid chain at lysine-17 that drives reversible albumin binding extending the plasma half-life to roughly 6 days in published pre-clinical models and supporting once-weekly dosing protocols
Drug Saf 2008;31(6):469-484